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Age-related neurodegenerative disease has been mechanistically linked with mitochondrial dysfunction via damage from
reactive oxygen species produced within the cell. We determined whether increased mitochondrial oxidative stress could
modulate or regulate two of the key neurochemical hallmarks of Alzheimer’s disease (AD): tau phosphorylation, and ß-amyloid
deposition. Mice lacking superoxide dismutase 2 (SOD2) die within the first week of life, and develop a complex
heterogeneous phenotype arising from mitochondrial dysfunction and oxidative stress. Treatment of these mice with catalytic
antioxidants increases their lifespan and rescues the peripheral phenotypes, while uncovering central nervous system
pathology. We examined sod2 null mice differentially treated with high and low doses of a catalytic antioxidant and observed
striking elevations in the levels of tau phosphorylation (at Ser-396 and other phospho-epitopes of tau) in the low-dose
antioxidant treated mice at AD-associated residues. This hyperphosphorylation of tau was prevented with an increased dose of
the antioxidant, previously reported to be sufficient to prevent neuropathology. We then genetically combined a well-
characterized mouse model of AD (Tg2576) with heterozygous sod2 knockout mice to study the interactions between
mitochondrial oxidative stress and cerebral Aß load. We found that mitochondrial SOD2 deficiency exacerbates amyloid
burden and significantly reduces metal levels in the brain, while increasing levels of Ser-396 phosphorylated tau. These
findings mechanistically link mitochondrial oxidative stress with the pathological features of AD.
Citation: Melov S, Adlard PA, Morten K, Johnson F, Golden TR, et al (2007) Mitochondrial Oxidative Stress Causes Hyperphosphorylation of Tau. PLoS
ONE 2(6): e536. doi:10.1371/journal.pone.0000536
INTRODUCTION
Mitochondria are a main source of potentially pathogenic reactive
oxygen species (ROS) such as superoxide, particularly in highly
metabolically active organs such as the brain and heart [1–3]. The
chief defense against superoxide produced during the course of
respiration is mitochondrial superoxide dismutase (SOD2). Mice
have been genetically modified to lack sod2 in specific tissues [1,4],
or systemically in multiple genetic backgrounds [5,6]. The
resulting phenotypes include neonatal or embryonic lethality
[5,6], cardiomyopathy [5,6], hemolytic anemia [7,8], seizures [6],
increased incidence of cancer [9], genomic instability [10],
mitochondrial biochemical defects [11,12], spongiform encepha-
lopathy [3], optic neuropathy [4], movement disorders [3,6] and
neurodegeneration [12]. These phenotypes arise due to endoge-
nous oxidative stress and several antioxidant interventions have
been applied to the sod2 nullizygous mouse model [2,3,13]. Some
of these interventions have striking efficacy in preventing
cardiomyopathy, extending lifespan, preventing spongiform en-
cephalopathy [2,3], reducing anemia [7], increasing mitochondrial
enzyme activity, reducing neurodegeneration and attenuating
gene expression characteristic of mitochondrially mediated spongi-
form encephalopathy [12,14].
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder that is associated with oxidative stress [15] and the
accumulation of two characteristic pathologies, neurofibrillary
tangles, composed primarily of hyperphosphorylated aggregates of
tau [16], and amyloid plaques, largely composed of aggregated Aß
[17]. Aß binds copper and zinc selectively in AD tissue, and Aß:Cu
complexes are a catalytic source of H2O2 [18,19]. The molecular
mechanism that results in an aggregation of Aß with increasing
age in the brain is still uncertain, but abnormal interactions with
biometals (principally copper and zinc) may play a prominent role
[15]. To aid in the development of therapeutic strategies for AD,
a number of animal models have been developed which
recapitulate the plaque pathology [20–22]. However, only recently
have transgenic mice been developed which model the two key
neuropathologies associated with AD [23]. These mice pro-
gressively develop both amyloid and tau pathology, which are both
associated with synaptic dysfunction. Of note in this genetic
model, Aß deposition preceded the development of phosphorylat-
ed tau, and the distribution of phospho-tau closely recapitulated
the distribution of tangles that characterize the human disease
[24]. More recently, transgenic mice were developed which
overexpressed mutant tau by 7–13 fold, resulting in mice that
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impaired cognition [25]. Mice that model mitochondrial dysfunc-
tion and Alzheimers disease have only recently been developed
[26,27]. Mice overexpressing mutant APP were crossed with mice
heterozygous for sod2, resulting in strains of mice with acceleration
of amyloid accumulation, in addition to increasing behavioral
defects in one strain [26].
A key question that remains unresolved in all currently available
animal models of AD, is how well do they model AD where there
are no mutations in either APP or tau? The majority of current
animal models of AD are based on the overexpression of mutant
forms of genes associated with AD linked to aggressive familial
mutations [20,23,25,28,29]. Therefore, a significant need exists for
the development of animal models of the neuropathology of AD,
which are not based upon overexpression of mutant human
proteins. Here we describe a novel model for AD neuropathology,
showing that mice that lack sod2 express AD-like hyperpho-
sphorylation of tau, the protein component of neurofibrillary
tangles. We show that this hyperphosphorylation of tau is
attributable to mitochondrial oxidative stress. We also show that
mice that are both transgenic for APP, and hemizygous for sod2,
incur a higher level of tau phosphorylation, higher amyloid burden
and decreased copper, zinc and manganese levels, consistent with
a synergistic interaction between APP and mitochondrial oxidative
stress in contributing to AD-like neocortical pathology.
METHODS
Animal husbandry
Sod2 nullizgyous mice of both sexes were genotyped between 2 and
3 days of age, and injected intraperitoneally with EUK189 at
either 1 mg/kg (low dose) or 30 mg/kg (high dose) daily from
3 days of age until sacrifice, as previously described [2,3].
EUK189 was purchased from Dalton Chemical Laboratories,
Inc (Toronto, Canada). Wild type animals as well as sod2
nullizygous mice were treated to control for compound specific
effects. Mice were killed at 18–21 days of age and cortex harvested
immediately for use in histological or biochemical studies.
Tg2576:sod2 hybrid mice were created by crossing C57BL/6 sod2
null mice (a kind gift of C.J. Epstein) to SJL mice to create F1
C57BL/6:SJL sod2 heterozygotes. These mice were then crossed to
APP mice (Tg2576 [20], on an identical genetic background), to
generate Tg2576:sod2 mice, which were maintained and bred as
previously reported [20]. Tg2576:sod2 mice, Tg2576 mice, and
C57BL/6:SJL F1 hybrid sod2 heterozygotes were maintained under
barrier conditions until 497–527 days of age, when they were killed
and neocortices were either harvested and frozen for biochemical
analysis, or fixed in neutral buffered formalin for histological
processing using standard protocols. We chose female Tg2576 mice
to study because they have more robust plaque changes [30]. All
animal procedures were carried out under approved IACUC animal
protocols at the Buck Institute, which is AAALAC accredited.
Immunohistochemistry
Parrafin embedded brain tissue was cut at a thickness of 8 mm, and
tissue sections were de-paraffinised with xylene and re-hydrated
through a stepwise series of ethanol solutions (100%, 95%, 70%).
Non-specific background was reduced by a 5 minute pre-
incubation in 0.5X PBS, in 10% methanol plus 3% hydrogen
peroxide for 20 to 30 minutes. Antigen retrieval was routinely
used with a commercially available kit (Antigen Unmasking
Solution, Vector Lab., Burlingame CA). All slides were blocked
(0.01X PBS, 5% v/v normal donkey serum, 0.1% Triton X-100)
for 2 hours at room temperature, after which the primary
antibody (rabbit anti-phospho-Ser 396 tau antibody, BioSource,
Camarillo, CA) was added and left over 2 nights at 4uC. To ensure
specificity of signal, a specific phospho-blocking peptide for
phospho Ser-396 was used on adjacent serial sections (BioSource),
which completely blocked the signal from the primary antibody.
The secondary antibody (1:500, Biotin-SP-conjugated donkey
anti-rabbit IgG, Jackson ImmunoResearch Lab, West Grove, PA)
was incubated for one hour at room temperature and the resulting
signal was visualized using the Vectastain ABC kit and VectaDAB
kit (Vector Laboratories, Burlingame, CA) according to the
manufacturer’s instructions. All slides were counterstained in
Mayer’s Haematoxylin for 30 seconds, and then dehydrated
before the application of cover-slips, and subsequent photography
using a digital camera (AxioVision v3.1, Carl Zeiss Vision). Silver
staining for detection of possible neurofibrillary tangles, was
performed as previously described [31], with the following
modifications: immersion in the alkaline solution was 10 seconds,
and the physical developer components for 25uC (10 mL solution
A+5 mL solution B+5 mL solution C) were used immediately after
mixing. Sections were developed in this solution until they had
turned pale to mid-grey (approximately 20 to 30 minutes).
For evaluating amyloid load, we cut 7 mm coronal sections from
formalin-fixed brain tissue. The sections were treated with 80%
formic acid for antigen retrieval before probing with monoclonal
antibody 1E8 that recognizes an epitope between residues 18 and
22 of Ab (Glaxo SmithKline, UK). All sections were imaged on
a Northern Light Illuminator (Imaging Research Inc, Ontario,
Canada) using a Spot RT-KE 2MP digital camera (Diagnostic
Instruments, MI, USA) equipped with a Nikkon 55 mm lens and
56 mm extension tube set. Each image was analyzed using
ImagePro Plus 5.1 (Media Cybernetics, MD, USA). For each
image an ‘‘area of interest’’ (AOI) line was drawn around the
margins of the brain occupied by the hippocampus and cortex.
The number of ß-amyloid-positive structures present in each
section were then quantitated using color selection to separate the
plaques from background labeling. A filter was also utilized to only
include structures that were greater than 10 pixels in size. This
data was expressed as the total number of ß-amyloid-positive
pixels in each section and was exported to Microsoft Excel for
analysis. Based upon the known size of each AOI, all values were
normalized to allow comparisons between sections of different
surface area and were expressed as pixels/mm
2. Average Aß load
was assessed in the cortex and underlying grey matter taken from
two sections from each animal and all counts represent Aß found
only in plaques. In all cases, the investigator undertaking the
analyses was blinded to animal genotype.
Western blotting and quantitation of phospho tau
Protein was extracted from mouse cortex by homogenizing in
tissue extraction buffer (50 mM Tris HCl (pH 7.4), 150 mM
NaCl, 1 mM EDTA, 1% Triton, 0.1% SDS) containing mini
complement protease inhibitors (Roche) at 4uC. Cellular debris
was removed by centrifuging at 10,000 rpm in a bench top
centrifuge for 5 minutes. Supernatant fractions were removed, and
protein concentrations determined using a BCA protein assay kit
(Pierce Biotechnology, Rockford, IL). Each sample was denatured
in standard SDS/Page loading buffer and 2.5 mg of protein run on
a NuPage 4–12% Bis Tris gels in MES buffer (Invitrogen,
Carlsbad, CA). Proteins were transferred onto a Immuno-Blot
PVDF membranes (Bio-Rad, Hercules, CA), according to the
manufacturer’s instructions. Blocking was carried in a standard
5% fat free milk solution in 1xTBS (0.05% Tween) for 1 hour at
room temperature. Five anti-phospho-tau antibodies were em-
ployed which were directed against specific residues that had been
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[32]; Thr-205, Ser-396, Ser-404, Ser-214, Thr-231 (Figure 1).
Anti-phospho tau primary antibodies (Biosource, anti phospho-
Thr 205, anti phospho-Ser 396, anti phospho-Ser 404, and anti
phospho-Thr 214, all rabbit) (Chemicon, Temecula, CA) were
typically used at a concentration of between 1:1000 to 1:10000,
diluted in blocking buffer. The secondary antibody was an HRP-
conjugated goat anti-rabbit (Pierce). Chemiluminescent detection
was conducted with the ECL Plus western blotting detection
system (Amersham Biosciences, Piscataway, NJ) and X-ray film
according to manufacturer’s instructions.
A number of preliminary blots were run for each antibody to
determine the optimal conditions for quantification of phosphor-
ylated tau. In these preliminary studies, the amount of protein was
varied per gel, or the concentration of primary antibody varied in
order to estimate the linear range of quantifiable phospho-tau.
Because the amount of tau protein in the sample could
potentially contribute to the amount of phosphorylation at specific
Figure 1. Mitochondrial oxidative stress causes hyperphosphorylation of tau. Western blots of cortical extracts from sod2 null mice treated with
1 mg/kg (n=8) of the catalytic antioxidant EUK189 or 30 mg/kg (n=7) of EUK189 (white bars), or wild-type mice (n=6, 1 mg/kg; n=7, 30 mg/kg)
treated comparably (black bars), were probed with the following antiphospho-tau antibodies; Thr 205, Ser 396, Ser 404, Ser 214, and Thr-231.
Quantitation of chemiluminesence was carried out in the linear range of detection for each of these antibodies, using a regression model to adjust for
the total amount of tau (results). P values for comparisons between each of the residues of phospho-tau were derived from the regression model,
after correcting for the total amount of tau per group.
doi:10.1371/journal.pone.0000536.g001
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Instead of using a normalized outcome (such as the ratio of
residue/tau), we adjust for the amount of tau using a simple linear
modeling approach. Specifically, for each residue we estimate the
model:
EY jTx, Geno, Tau ½  ~b0zb1I Geno~{={ ðÞ zb2I
Tx~30mg=kg ðÞ zb3I Geno~{={ ðÞ   IT x ~30mg=kg ðÞ zb4tau
where I(Geno=2/2) is the indicator function (=1 if genotype is
2/2, 0 otherwise, Tx is treatment). This model permits the
testing and estimation of dose effects within genotype and
similarly, genotypes within dose groups. The inference was
derived using robust standard errors [33]. Note, in none of the
models was the amount of total tau significantly associated with
a specific outcome (i.e., the p-value of the test of b4=0was .0.05
for all residues). Comparison between specific groups using the
above regression modeling after adjusting for total tau and their
associated p-values are listed in Figure 1.
Immunoprecipitation of phosphorylated tau
Immunoprecipitation was carried out using the SeizeH Primary
Immunoprecipitation Kit from Pierce, according to the manu-
facturer’s instructions. 100 mg of Tau-5 anti-tau antibody
(BioSource) was coupled to the 200 ml of AminoLinkH Plus
Coupling Gel Protein as per the manufacturer’s instructions. Brain
extracts (1.2 mg per mouse, for a total of 6 mg in 750 ml) were
pooled from five 18-day-old sod2 null mice that had been treated
with a low dose of Euk189, or brain extracts (50 ml each) from nine
female Tg2576:sod2+/2 mice were pooled for a total of 1.8 mg in
450 ml. The pooled extracts were diluted to 5 ml with Binding
Buffer, the 200 ml of antibody-coupled resin added, and the
mixture rotated overnight at 4uC. Subsequent washes and elution
were carried out as per the manufacturer’s instructions. All bound
tau protein was found to be eluted from the resin in the first 200 ml
elution fraction.
Proteolytic digestion of immunoprecipitated tau
Phosphorylated tau protein was either immunoprecipitated from
single mutant (sod22/2) mouse brain tissue as described above
and was directly processed following a manual in-solution
digestion protocol. Approximately 0.3–0.4 mg of immunoprecipi-
tated tau in elution buffer (100 mM glycine) was brought to pH
8.0 by adding 50 mM NH4HCO3 buffer (final total volume 60 ml).
Subsequently, acetonitrile (ACN) was added (40% final concen-
tration) to denature the protein. The protein was incubated at
60uC for 30 min with a 500-fold molar excess of reducing reagent
DTT over the number of cysteine residues in tau, followed by an
incubation at 37uC for 45 min after adding a 1100-fold molar
exess of alkylating reagent iodoacetamide (DTT and iodoaceta-
mide were both purchased from Sigma, St. Louis, MO). After
dilution of the reaction mixture to 10% ACN, the sample was
incubated with 40 ng sequencing grade trypsin (Promega,
Madison, WI) at 37uC for 8 hours. The resulting tryptic peptides
were acidified with formic acid, and then subjected to mass
spectrometric analysis.
Mass Spectrometric Analysis (ESI-MS/MS)
The proteolytic peptide mixtures were analyzed by reverse-phase
nano-HPLC-MS/MS. Briefly, peptides were separated on an
Ultimate nanocapillary HPLC system equipped with a PepMap
TM
C18 nano-column (75 mm I.D.615 cm) (Dionex, Sunnyvale, CA)
and CapTrap Micro guard column (0.5 ml bed volume, Michrom,
Auburn, CA). Peptide mixtures were loaded onto the guard
column and washed with the loading solvent (H2O/0.05% formic
acid, flow rate: 20 ml/min) for 5 min, then transferred onto the
analytical C18-nanocapillary HPLC column and eluted at a flow
rate of 300 nl/min using the following gradient: 2% B (from 0–
5 min), and 2–70% B (from 5–55 min). Solvent A consisted of
0.05% formic acid in 98% H2O/2% ACN and solvent B consisted
of 0.05% formic acid in 98% ACN/2% H2O. The column eluant
was directly coupled to a ‘QSTAR Pulsar i’ quadrupole
orthogonal TOF mass spectrometer (MDS Sciex, Concorde,
Canada) equipped with a Protana/ProXeon nanospray ion source
(ProXeon Biosystems, Odense, Denmark). The nanospray needle
voltage was typically 2300 V in the HPLC-MS mode. Mass
spectra (ESI-MS) and tandem mass spectra (ESI-MS/MS) were
recorded in positive-ion mode with a resolution of 12,000–15,000
FWHM. For collision induced dissociation tandem mass spec-
trometry, the mass window for precursor ion selection of the
quadrupole mass analyzer was set to 61 m/z. The precursor ions
were fragmented in a collision cell using nitrogen as the collision
gas. Spectra were calibrated in static nanospray mode using MS/
MS fragment-ions of a renin peptide standard (His immonium-ion
with m/z at 110.0713, and b8-ion with m/z at 1028.5312)
providing a mass accuracy of #50 ppm. Samples were run at least
twice by HPLC-MS/MS. Mass lists were generated of potential
phospho-peptides that were observed as ESI-MS fingerprints but
were not selected by ESI-MS/MS in the first HPLC run. These
mass lists were entered as inclusion lists to the Information
Dependent Acquisition of the QSTAR instrument (to be selected
for MS/MS) in subsequent runs.
Database searches for protein identification and
additional bioinformatics programs
ESI-MS/MS data: ESI-MS/MS data were submitted to our in-
house search engine Mascot analyzing peptide sequence informa-
tion from tandem mass spectra. The search engine Mascot uses
a probability based ‘Mowse Score’ to evaluate data obtained from
tandem mass spectra, e.g. for a score.37, protein matches are
considered significant [34]. All acquired MS/MS spectra of phos-
phorylated peptides were interpreted and inspected ‘‘manually’’
and compared to the MS/MS spectra of their corresponding non-
phosphorylated peptides.
ESI-MS data: In order to obtain reliable peak lists from ESI-
MS data that were generated during an LC-MS run, the programs
Mascot Distiller (version 1.1.1) and Mascot Distiller MDRO
Software Developers Kit (version 1.1.1) were purchased (Matrix
Sciences, London, United Kingdom). An in-house developed java
program named ‘‘MS-Assign’’ was used to interface with the
Mascot Distiller software that was used for peak picking and to
extract and compile ESI-MS peak lists from the LC-MS runs.
Subsequently, ESI-PMF peak lists were submitted to our Mascot
search engine or Protein Prospector.
Evaluation of Aß load
We estimated Aß load using both immunohistochemistry (de-
scribed above) and the DELFIAH Double Capture ELISA (Ritchie
et al., 2003). Briefly, brain tissues (,0.2 g) were homogenized in
PBS at a ratio of 1:10 (w/vol), and centrifuged at 100,000 g for
1 hr. The pellet was resuspended in the original volume and
further solubilized with guanidine HCl to a final concentration of
5 M followed by centrifugation at 16,000 g for 20 minutes. To
measure Aß40 or Aß42, the supernatants were diluted 1:10 with
blocking buffer (0.25% casein or Superblock (Pierce) in phosphate-
Mitochondrial Oxidative Stress
PLoS ONE | www.plosone.org 4 June 2007 | Issue 6 | e536buffered saline with 0.025% Tween-20) before adding to the plate.
For the detection of Aß40 or Aß42 in the 100,000 g soluble fraction,
50 mlofthesolublefractionswereappliedtotheELISAplates.Plates
were coated with either G210 (for Ab40) or G211 (for Ab42)
antibodies, which are specific for the C-terminus of Ab, then blocked
with 0.5% (w/v) casein/PBS or Superblock/PBS buffer (pH 7.4).
After washing the plates, WO2-Biotin was added to the wells. The
epitope for WO2 is within residues 5–8. Ab40 and Ab42 peptide
standards and samples were assayed in triplicate, and incubated
overnight at 4uC. The plates were washed, europium labelled
streptavidin added, and then developed with enhancement solution.
Analysis was carried out using the Wallac Victor
2 1420 Multilabel
Plate Reader (PerkinElmer, Melbourne, Australia) with excitation at
340 nm and emission at 613 nm.
Levels of the amyloid precursor protein (APP), the parent
molecule of Aß, were quantitated by Western blot using the
antibody 22C11 (Boehringer), which detects both the transgene-
expressed human APP as well as the endogenous mouse APP.
Briefly, snap-frozen tissues were thawed and homogenized in PBS
(pH 7.4, 2 ml) and centrifuged at 100,000 g for 30 minutes. The
pellet was resuspended 1:1000 (w/v) in PBS and aliquots dissolved
by extensive boiling in 8% SDS sample buffer containing 10%
mercaptoethanol prior to separation on PAGE.
Statistical analysis was carried out between genotypes using
a non-parametric t-test (two-sided) (PRISM, Graphpad, San
Diego, CA).
ICP-MS evaluation of metal content of soluble and
insoluble amyloid fractions
Cortical samples were sonicated in 1 ml of PBS, centrifuged at
100,000 g for 30 minutes 4uC. The supernatant was collected and
the pellet was resuspended in 1 ml of PBS.
A 500 ml aliquot of each brain pellet suspension was lyophilised.
Samples were assayed by inductive-coupled plasma mass spec-
trometry according to our previously published procedures [35].
Results are expressed as the average of the three triplicates in
micrograms of metal per g of protein (mg/g). Note: The levels of
cobalt and aluminium in the samples were below detectable levels.
Statistical analysis was carried out between genotypes using a non-
parametric t-test (two-sided).
RESULTS
Mitochondrial oxidative stress causes
hyperphosphorylation of tau
To test whether mitochondrial oxidative stress causes hyperpho-
sphorylation of tau, we studied sod2 null mice that were treated
with a catalytic antioxidant (EUK189). A low dose of EUK189
(1 mg/kg) rescues the peripheral phenotypes in these mice and
extends the lifespan up to 3 weeks [2], while revealing a spongi-
form encephalopathy [14] and severe behavioral disorder [2]. This
treatment response is concordant when sod2 null mice are treated
with other closely related antioxidant regimens (EUK8, EUK134,
analogues of EUK189, [2]). In contrast, treating sod2 null mice
with a high dose of EUK189 (30 mg/kg) improves survival,
behavioral abnormalities, and transcriptional responses associated
with oxidative stress, in conjunction with increasing activities of
mitochondrial enzymes that are sensitive to mitochondrial
oxidative stress [2,14], as well as preventing spongiform neuropa-
thology. Sod2 null mice that are not treated with antioxidants die
within the first week of life from peripheral organ failure without
any observable brain pathology [5,11]. Hence they are unsuitable
to examine the effects of endogenous oxidative stress on the brain.
By comparing the low and high dose antioxidant treated groups
of mice, we were able to contrast the effects of mitochondrial
oxidative stress on the potential phosphorylation status of tau.
Mice were killed (N=6–8 per treatment group), frontal cortices
were harvested, and protein was extracted and western blotted for
quantification of tau and phosphorylated tau. To control for drug
specific effects, wild-type mice were also treated with either low or
high dose of EUK189 for the same period of time. Untreated sod2
null mice on this genetic background do not survive long enough
(,1 week, [2]) to serve as a negative control.
First we asked whether lack of sod2 caused an increase in the
abundance of tau itself (Figure 1A). Two tailed non-parametric t-
tests were carried out to determine differential levels of total tau in
frontal cortices between sod2 null mice and wild type controls. No
significant differences were found between genotypes in either low
(1 mg/kg) or high (30 mg/kg) EUK189 treated mice (Figure 1A).
Next we asked if treatment with EUK189 within each genotype
could have an effect on total tau levels. Interestingly, in wild type
mice, there was a statistically significant drop in total tau (15%), as
a result of increasing the concentration of EUK189 from 1 mg/kg
to 30 mg/kg. In sod2 null mice, the same trend was observed;
increasing the dosage of EUK189 from 1 mg/kg to 30 mg/kg
significantly decreased the total load of tau by 45%.
To determine whether lack of mitochondrial sod2 could alter
the phosphorylation status of specific tau residues (Ser-396, Ser-
404, Ser-214, Thr-231, and Thr-205), we normalized the amount
of total tau per animal through a regression analysis (see methods).
Thus, we examined the level of phosphorylated tau at each of
these residues without being confounded by the differential loads
of tau seen between groups in Figure 1A. Treatment with
EUK189 has no effect on phospho-tau epitopes in wild type
controls, however EUK189 normalized phospho-tau epitopes in
the sod2 mutant mice (Figure 1).
Figure 1B shows that in the low dose treated sod2 null mice,
there is a most prominent 7-fold increase in the hyperpho-
sphorylation of tau at Thr-205 in sod2 null compared to wild type
mice (p,0.001). There is also a trend for reduced phosphorylation
of Thr-205 due to a higher dose of antioxidant treatment,
although this does not reach statistical significance (Figure 1B).
Figure 1C shows that lack of sod2 causes a more than 2-fold
significant increase in the level of hyperphosphorylation of Ser-396
(p,0.001) over treatment-matched controls, and that increasing
the dose of antioxidant significantly attenuates the level of
hyperphosphorylation (p=0.02). Similarly, for Ser-404, mitochon-
drial oxidative stress also increases the level of hyperphosphoryla-
tion of tau to 3-fold over treated controls (Figure 1D, p,0.001),
while increasing the dosage of antioxidant to reduce oxidative
stress rescues the hyperphosphorylation to wild-type levels
(p,0.04). Ser-214 is the only phospho-tau epitope that was
hypo-phosphorylated in the low dose sod2 null mice (p,0.001),
with increased dose of antioxidant again normalizing the level of
hypophosphorylation to wild-type levels (Figure 1E). Figure 1F
shows an increase in the phosphorylation of Thr-231 (1.3 fold,
p=0.004) in the low-dose EUK-189 treated sod2 null animals,
which is correspondingly rescued with high-dose EUK-189
antioxidant treatment (p=0.004). Finally we asked if there were
any sex specific effects with regard to differential phospho-tau
loads between treatment groups, and there were no significant
trends detected (data not shown).
In order to validate our initial observations of hyperpho-
sphorylation of tau at residues associated with AD in sod2 null
mice, we employed mass-spectrometry techniques as an alternate
approach. To maximize the likelihood of detecting multiple sites of
phosphorylation of tau, we immunoprecipitated total tau protein
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Tau-5 monoclonal antibody, which detects both phosphorylated
and non-phosphorylated forms of tau (Biosource). After releasing
tau from the antibody, the protein was reduced, alkylated and
digested with trypsin (see methods). Peptides were analyzed by
MALDI TOF MS for peptide mass fingerprint analysis, then
nano-HPLC-ESI-MS/MS. To determine site(s) of phosphoryla-
tion within tau protein the ESI-MS/MS spectra were searched by
Mascot, and spectra shown to contain phosphorylated peptides
were verified by manual inspection. Our mass spectrometric
results corresponded with the positive phospho-antibody probing
of tau for phosphorylation sites shown in Figure 1, such as
phospho Ser-404, phospho Thr-231, and phospho Ser-396 (as
determined by ESI-MS/MS and ESI-MS). The tryptic peptides
covering phosphorylation site phospho Thr-205 clearly showed
mono- and diphosphorylation events, but due to the complex
assembly of potential serine and threonine residues the mass
spectrometric studies could not provide unambiguous assignment
of Thr-205 as the phosphorylation site. Additional data seen in our
mass-spec data provided clear evidence for the site of phosphor-
ylation of phospho Thr-181 and phospho Ser-159, two well-
characterized sites of phosphorylation of tau in AD [32]. Table 1
shows the range of sites identified by mass spectrometry in brain
tissue isolated from sod2 null mice.
We next investigated whether pathological sequelae associated
with hyperphosphorylation of tau in AD were also present in brain
sections from sod2 null mice. We used a modified Gallyas stain to
detect possible neurofibrillary tangles (NFTs) in tissue sections
(methods). We also used Schiff staining to determine if any other
pathologyrelated toAD,suchas insoluble amyloidplaqueswere also
present [36]. We were unable to identify any pathology relating to
NFTs or aberrant amyloid metabolism using either of these methods
in sections throughout the brain from 3-week-old sod2 null mice on
either low or high dose EUK189 (data not shown).
Mitochondrial oxidative stress increases
phosphorylation of tau in Tg2576:sod2 mice
Having determined that mitochondrial oxidative stress causes
hyperphosphorylation of tau, and that this can be ameliorated by
antioxidant treatment, we next asked if there might be a synergistic
interplay between aberrant amyloid metabolism and mitochon-
drial oxidative stress. Therefore, we crossed the Tg2576 (APP)
mouse to hemizygous sod2 mice to create Tg2576:sod2 mice as
described above. These double mutant mice are on an identical
genetic background to Tg2576 mice. Therefore we aged four
female genetically distinct groups (Tg2576, Tg2576:sod2, sod2+/2,
and wild-type controls) on the same genetic background as the
Tg2576 mice (F1 C57BL/6J: SJL hybrids), to approximately
16 months of age (when brain amyloid pathology is uniformly
well-established in the Tg2576 model [20]) in order to investigate
the effects of increased mitochondrial oxidative stress on amyloid
and potential tau pathology. No difference in survival between the
4 groups was observed up to this age. The animals were sacrificed
and the brains harvested, with half the brain being fixed and
paraffin embedded for histological studies, while cortex from the
other half was snap frozen for biochemical studies. Protein was
extracted and equivalent amounts of protein from the 4 genetic
groups were evaluated for levels of phospho Ser-396, a widely used
epitope for detecting NFTs in AD, and readily induced in the
brains of sod2 null mice compared to controls (Figure 1).
Levels of phospho Ser-396 in sod2+/2 and Tg2576 mice were
not significantly different from WT mice, indicating that oxidative
stress induced by either loss of 50% sod2 activity [9] or cerebral b-
amyloid [19], was insufficient to impact levels of Ser-396
phosphorylation. However, we detected a significant 45% increase
in the levels of phospho Ser-396 (p,0.003) in Tg2576:sod2 over
the levels in Tg2576 or sod2+/2 alone (Figure 2). This is consistent
with synergy between amyloid load and increased mitochondrial
oxidative stress in the hyperphosphorylation of tau.
Sections from fixed hemispheres of the same animals where Ser-
396 phospho-tau levels were assayed in Figure 2 were stained for
phospho Ser-396. In contrast to non-transgenic sod2 null mice, we
detected dystrophic neurites positive for phospho tau (Figure 3), in
a pattern previously reported to be associated with plaque
pathology [37]. Absorption with the peptide specific for the
phospho Ser-396 epitope abolished detectable signal (Figure 3B.).
Comparison of IHC for Ser-396 between Tg2576 and Tg2576:sod2
mice (n=3 each) revealed no qualitative or quantitative
differences between the groups at the immunohistochemical level
for hyperphosphorylated tau and no neurofibrillary tangles.
Table 1. Tau phosphorylation sites identified in sod2 null mouse brain tissue
..................................................................................................................................................
residues Detected by Antibody % change
a mass spec ID
b phospho peptide observed by mass spectrometry P site ID
Thr-205 Yes 728 +/2
c MS
c
Ser-404 Yes 309 +/2 S
396PVVSGDTpS
404PR
406 MS/MS
d
Ser-396 Yes 210 +/2 T
386DHGAEIVYKpS
396PVVSGDTpS
404PR
406 MS
e
Ser-214 Yes 63 + T
212PpS
214LPTPPTREPK
224 MS/MS
Thr-231 Yes 147 + V
226AVVRpT
231PPKSPSASK
240 MS/MS
Ser-202 Yes NS + S
195GYSSPGpS
202PGTPGSR
209 MS/MS
Thr-181 No 2 + T
175TPSPKpT
181PPGSGEPPK
190 MS/MS
f
Ser-159 ND 2 + G
156AApS
159PAQKGTSNATRIPAK
174 MS/MS
a: Percent changes of listed residue in sod2 null mice relative to sod2wild-types (normalized to 100%, see Figure 1), both treated with EUK189 at 1 mg/kg quantitated by
Western blotting with monoclonal antibodies for the indicated tau residues, NS– not significant, ND – not done.
b: identifications were positive (+) if a MS/MS spectrum could be unambiguously interpreted to identify a unique phosphorylation site. In three cases (+/2) assignments
were based on MS or MS/MS data and alternative sites were possible.
c: several matching phospho peptides observed by ESI-MS (i.e., peptides: mono-/di-phosph. S195-R209 and mono-/di-phosph. S181-R209);
d: Phosphorylate site possibly on Ser-404, Thr-403 or Ser-400;
e: peptide observed with 1P and 2P groups;
f: differences in peptide sequence (human vs. mouse) likely accounting for negative antibody result (homologous human peptide: TPPAPKTPPSSGEPPK);
g: no antibody available for Ser-159.
doi:10.1371/journal.pone.0000536.t001
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Tg2576 mice
We next investigated the effect of sod2 deficiency and Euk189
treatment upon brain Aß burden in APP transgenic mice.
We used two different methods to test this hypothesis; we
evaluated Aß plaque load by immunohistochemistry and also
assessed Aß protein by ELISA in each of the different treatment
groups (Tg2576+EUK189, Tg2576, Tg2576:sod2). The immuno-
histochemistry data (Figure 4) indicate that the Tg2576:sod2
animals have a 32% and a 29% increase in plaque burden as
compared to Tg2576+EUK189 and Tg2576 animals respectively,
which does not reach statistical significance (p=0.18, p=0.22).
The ELISA data (Figure 4) demonstrates that Tg2576 and
Tg2576:sod2 animals have a 73% (p=0.01) and 52% (p=0.3)
increase in total Aß1-40 and a 172% (p=0.04) and 265%
(p=0.02) increase in total Aß1-42 respectively, as compared to
Tg2576+EUK189 animals. Tg2576:sod2 animals also show a 12%
decrease in total Aß1-40 and a 34% increase in total Aß1-42 as
compared to Tg2576 mice. These findings indicate that while the
sod2 mutant allele did not have a discernable effect on total Aß
levels, the antioxidant treatment did drop Aß levels significantly.
The precursor to Aß, the amyloid precursor protein (APP), also
showed significant modulation according to genotype. As shown in
Figure 5, the sod2 mutation present in the Tg2576:sod2 animals
resulted in a significant elevation (87%, p=0.002) in total APP levels
as compared to the Tg2576 background strain and a 47% (p=0.02)
increase compared to Tg2576 mice treated with EUK189.
Decreased metal content in Tg2576:sod2 mice
Because APP overexpression lowers cellular copper [38,39] and
decreased copper levels exacerbates amyloid pathology [40,41],
we investigated whether the synergistic interplay between sod2
ablation and Alzheimer pathology in Tg2576 transgenics is
reflected by lowered brain metal levels.
As shown in Figure 6, there is a decrease in copper levels in both
the supernatant (25%, p=0.01) and pellet (16%, p=0.02) brain
fractions of Tg2576:sod2 animals as compared to the Tg2576
background strain. Similarly, there is a significant decrease in
manganese levels in both the pellet (23%, p=0.01) and supernatant
(35%, p=0.0002) fractions of Tg2576:sod2 animals as compared to
the background Tg2576 mice. There is also a significant increase in
manganeselevelsintheEUK189treatedTg2576 mice,ascompared
to the Tg2576 background strain, in both the pellet (113%,
p=0.002) and supernatant (91%, p=0.0002) fractions. Similar
trends are also shown for zinc, which shows a significant decrease in
pellet (21%, p=0.001) and supernatant (18%, p=0.02) levels in the
Tg2576:sod2 animals as compared to the background Tg2576 mice.
We also found a significant increase in supernatant zinc levels (12%,
p=0.05) in the EUK189-treated Tg2576 animals as compared to
the background Tg2576 mice.
Consistent with previous reports [38–41] and with an in-
teraction of copper in our experimental system, we found that
there is a significant inverse correlation between brain APP levels
and both pellet (p=0.0005) and supernatant (p=0.02) copper
levels (Figure 7) in the untreated transgenic mice. This implies that
the decreased Cu levels in the APP:sod2 double mutants
(Figure 6A&B) are caused by elevated APP expression.
Figure 2. Mitochondrial oxidative stress results in a synergistic
increase in the levels of phospho-tau in Tg2576 mice. Data show the
mean6SD levels of Ser-396 phospho-tau assayed by Western blot of
cortical extracts from mice of <500 days of age from each of the
following genotypes: wild-type n=4, sod2+/2n=4, Tg2576 n=8,
Tg2576:sod2 n=9 (all matched for genetic background). A non
parametric t test was carried out between genotypes, and a significant
increase in phospho tau in the Tg2576:sod2 mice was observed,
compared to controls.
doi:10.1371/journal.pone.0000536.g002
Figure 3. Immunohistochemical identification of phospho-tau positive
dystrophic neurites in Tg2576:sod2 mice. (a) Immunohistochemistry for
anti Ser-396 was carried out as described in the text, and positivity was
observed surrounding senile plaques in the brains of Tg2576:sod2 mice.
(b) In order to ensure specificity, we also tested the effects of
preadsorbing the Ser-396 antibody with the peptide the antibody was
raised against. This abolished the staining seen around the plaques.
doi:10.1371/journal.pone.0000536.g003
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and supernatant fractions of the Tg2576:sod2 mice compared to
the control Tg2576 mice. SOD2 is a homotetramer requiring Mn
for its catalytic activity. Our observations of a 23–35% decrease in
Mn in both the pellet and supernatant fractions from the brains of
Tg2576:sod2 mice compared to controls is consistent with the loss
of SOD2. We also observed a 91–113% increase in the levels of
Mn in the brains of mice treated with EUK189, which is a Mn-
containing catalytic antioxidant. This is consistent with EUK189
or its bound Mn accumulating within the brain.
DISCUSSION
Mitochondria are the chief source of ROS within the cell, and age-
related oxidative damage in the brain has been associated with
neurodegenerative diseases such as Alzheimer’s and Parkinson’s
diseases [15]. We tested the hypothesis that mitochondrial
oxidative stress could contribute to the two pathological hallmarks
of AD, amyloid burden and hyperphosphorylation of tau. We
initially evaluated the brains of 3-week old sod2 null animals
treated with low and high doses of the catalytic antioxidant, EUK-
189. These mice would die within the first week of life unless
treated with antioxidants [2]. We previously developed the
paradigm of treating sod2 null mice with differential doses of
catalytic antioxidants, whereby at a low dose of treatment (1 mg/
kg of catalytic antioxidant), the peripheral phenotypes are rescued
and lifespan is extended, but a severe spongiform pathology with
neurodegeneration develops by 3-weeks-of-age [12]. At high doses
of catalytic antioxidant (30 mg/kg), the spongiform pathology is
completely prevented, and the accompanying neurodegeneration
is attenuated [2,12]. Thus, we could compare the changes in
amyloid/tau in the brains of wild-type and sod22/2 mice treated
with low and high doses of antioxidant (Figure 1) in order to test
the hypothesis that oxidative stress from mitochondrial dysfunction
promotes AD-like pathology.
We did not find evidence of increased amyloid burden in sod2
nullizygous neonatal mice, possibly because endogenous mouse Aß
has three amino acid substitutions that prevent mouse Aß from
being precipitated by synaptic copper and zinc [42]. However, we
did find a striking increase in the levels of hyperphosphorylated tau
at 3 weeks of age, which responded to catalytic antioxidant
therapy (Figure 1).
Figure 4. Exacerbation of amyloid load by genetic combination of lack
of sod2 and overexpression of APP. (a) Immunohistochemistry
quantitation (area occupied by Aß/mm2) did not demonstrate any
significant alterations in total Aß plaque burden, although there is an
,30% increase (p=0.2) in plaques in the Tg2576:sod2 animals as
compared to other groups. (b) ELISA quantitation demonstrates that
EUK189 treatment significantly modulates Aß levels. Furthermore,
genetically combining lack of sod2 with overexpression of mutant APP
elevates Aß levels in the Tg2576 mouse. The data indicate mean6SD.
doi:10.1371/journal.pone.0000536.g004
Figure 5. APP levels are elevated by genetic combination of sod2
with Tg2576 mice. The data indicate mean6SD APP levels in brain
assayed by western blot. As compared to the baseline Tg2576 levels,
APP protein was marginally higher in Tg2576 mice treated with EUK189
(29% increased, p=0.2), but markedly elevated by the presence of the
sod2 mutation (88% increased, p=0.002).
doi:10.1371/journal.pone.0000536.g005
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PLoS ONE | www.plosone.org 8 June 2007 | Issue 6 | e536We observed a significant increase in the level of hyperpho-
sphorylation in 4 out of 5 specific residues evaluated compared to
control wild-type animals (Table 1). We did observe one residue
(Ser-214) that was hypophosphorylated in response to mitochon-
drial oxidative stress. The phosphorylation status of various
residues in tau results from a complex interplay between the
inhibition and activation of kinases and phosphatases specific for
individual residues. A recent report shows that a peptidyl-prolyl
cis/trans isomerase (Pin1) caused hypophosphorylation of Thr-
231, Thr-212, Ser-396, and Ser-404 in response to an extracellular
hydrogen peroxide stress in primary neuronal cultures isolated
from neonatal rats[43]. Hence, extracellular oxidative stress can
cause hypophosphorylation of specific residues in tau. In contrast,
we show here that intracellular oxidative stress appears to cause
hyperphosphorylation in most residues we studied (table 1). Each
of these hyperphosphorylated residues has been previously
associated with aggregated hyperphosphorylated tau in AD [32],
and in the high-dose treated sod2 null animals, we observed
a significant normalization of phosphorylation toward wild-type
levels of phosphorylation in 3 out of 4 residues which were
hyperphosphorylated (Figure 1). Thr-205 did not reach signifi-
cance (although a trend consistent with the other three residues
Figure6.Metallevelsareloweredbygeneticcombinationoflackofsod2andoverexpressionofAPP.Dataindicatemean6SDbrainmetallevelsinthe
various genotypes, as indicated. This revealed a significant decrease in insoluble (16%) (A) and soluble (25%) (B) Copper levels, insoluble (23%) (C)a n d
soluble (35%) (D) Manganese levels, and insoluble (21%) (E) and soluble (18%) (F) Zinc levels in the Tg2576:sod2 animals compared to the Tg2576
background strain. EUK189 treatment increased soluble (91%) and insoluble (113%) Manganese and soluble (12%) Zinc levels in the Tg2576 animals.
doi:10.1371/journal.pone.0000536.g006
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Overall, we conclude that hyperphosphorylated tau which is
caused by mitochondrial oxidative stress could be resolved with
appropriate antioxidant therapy.
A number of prior studies have found associations between
mitochondrial dysfunction and AD, and animal models of AD
[26,44–46]. Aß inhibits mitochondrial alcohol dehydrogenase
[47,48] and cytochrome oxidase [49] leading to increased mito-
chondrial oxidative stress and apoptosis [47]. A recent report also
demonstrated a 9–11 fold increase in the expression of SOD2 by
immunohistochemistry in the hippocampus of Alzheimer patients
compared to controls, indicating a possible upregulation of antioxi-
dant defenses in response to a pro-oxidant environment within the
brain of AD patients [50]. To investigate the consequences of
increased mitochondrial oxidative stress in the context of an
established mouse model of AD, we crossed the Tg2576 mouse to
mice heterozygous for sod2, a model of mild mitochondrial oxidative
stress [9,51,52]. Concomitant with our observations of increased
hyperphosphorylation of tau as a consequence of sod2 knockout as
described above (Figure 1), we investigated the levels of Ser-396
phospho-tau, which is characteristically elevated in AD [32], in the
brains of double mutant mice compared to controls. We found
arobustincreaseinthelevelsofphosphoSer-396asaconsequenceof
increased mitochondrial oxidativestress,aboveand beyond that seen
in either parental control line, Tg2576 mice alone, or sod2 hetero-
zygotes (Figure 2). This implies that there is a synergistic interplay
betweenmitochondrial dysfunctionand amyloid burden that leadsto
hyperphosphorylation of tau. We also found a relationship between
thelevelofoxidativestressandthelevelofamyloidburden(Figure4).
A recent reportalsofound evidenceof oxidative stressbeinglinked to
tau-mediated neurodegeneration in drosophila [53].
The trends we observed, of increased amyloid burden
(Figure 4A) and Aß42 (Figure 4C) as a result of sod2 heterozygosity,
is consistent with a previous report where amyloid load was
increased by approximately 2 fold compared to controls through
genetic combination of sod2 heterozygotes with the Tg19959
model of AD [27]. However, a more recent report observed
decreased plaque burden in the parenchyma, with increased
vascular amyloid, gliosis and exaggerated neurocognitive deficits
as a consequence of sod2 heterozygosity in J20 APP transgenic
mice [26]. It is worth noting that Esposito et al., also found
enhanced loss of microtubule-dependant protein 2 (MAP2) that
was APP/Aß dependant in their sod2/APP model (which differs
from the model we report here). MAP2 is involved in maintaining
microtubule integrity like tau, and depletion of MAP2 is often
observed in association with hypephosphorylation of tau[54].
Hence it is possible that the J20 APP/sod2 mice[26], may also be
experiencing hyperphosphorylation of tau, given the reported
apparent loss of MAP2 in in the brains of these mice. Collectively,
these three studies ([26,27], and the data we report here) confirm
that the SOD2 allele impacts upon AD-like pathology, but clearly
the effects vary according to the AD mouse model utilized. Our
study is the first to describe an association between SOD2
knockout or antioxidant-modulated oxidative stress and tau
phosphorylation, which has not been investigated previously.
Previous studies have demonstrated that copper and iron levels
in the brains of transgenic mice are lowered by expressing mutant
APP or the carboxyl terminus of APP [39–41]. Consistent with
metal deficiency fostering amyloid accumulation, we have pre-
viously found that amyloid clearance induced by clioquinol is
associated with an elevation of cortical zinc and copper in the
brains of Tg2576 mice [55]. Our current findings indicate that
brain Cu, Zn, Fe, and Mn levels are all decreased as a consequence
of genetic combination of Tg2576 and sod2 heterozygotes. While
the significance of this finding is not clear, these metals all
participate in essential cellular function. It is likely that the drop in
energy that results from the mitochondrial damage leads to a loss
of brain metals. Decreased intracellular copper levels may
exacerbate amyloid pathology [40,41] by a mechanism that is
not yet clear. Therefore, the drop in brain copper levels induced
by the Tg2576:sod2 double mutation may contribute to the
increased amyloid burden in double mutants.
In summary, we have shown that mitochondrial oxidative stress
per se causes hyperphosphorylation of tau, and that this can be
prevented through appropriate antioxidant treatment (Figure 8).
We have also demonstrated that the aggregate amyloid burden in
a well established mouse model of AD (the Tg2576 mouse) is
influenced by mitochondrial oxidative stress. This has implications
for how we view mouse models of AD, in that to our knowledge,
this is the first mouse model of AD that recapitulates two of the
canonical hallmarks of AD pathology: plaques, and hyperpho-
sphorylated tau, without resorting to overexpression of both
mutant human proteins. Hyperphosphorylated tau is a component
of neurofibrillary tangles, the formation of which is closely
associated with the dementia process in AD. These findings
encourage the use of ROS-scavenging antioxidants as being of
potential therapeutic utility in AD.
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Figure 7. APP vs. copper correlation. Levels of APP and Copper in the
soluble and pellet phases of brain homogenate from untreated Tg2576
and Tg2576:sod2 crossed mice (pooled) were compared graphically and
found to correlate strongly (* p,0.02).
doi:10.1371/journal.pone.0000536.g007
Figure 8. Model of potential interactions between increasing Aß,
decreased activity of SOD2, and a resultant increase in the
hyperphosphorylation of tau. As levels of Aß increase with age, this
causes a concomitant decrease in the activity of SOD2, which in turn
leads to increased aggregation of Aß. The resulting pro-oxidant state of
the cell causes hyperphosphorylation of tau.
doi:10.1371/journal.pone.0000536.g008
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